Search for: "Courtenay Brinckerhoff"
Results 81 - 92
of 92
Sort by Relevance
|
Sort by Date
23 Nov 2010, 8:40 am
Maebius and Courtenay C. [read post]
14 Sep 2010, 10:45 am
Over at PharmaPatents, Courtenay Brinckerhoff has a post "Pharma Cases Dominate New USPTO Obviousness Examination Guidelines. [read post]
14 Sep 2010, 10:45 am
Over at PharmaPatents, Courtenay Brinckerhoff has a post "Pharma Cases Dominate New USPTO Obviousness Examination Guidelines." [read post]
8 Jul 2010, 5:00 am
Kappos: Effects on Biotechnology Patents Some New IP Blogs: PharmaPatentsBlog by Courtenay Brinckerhoff and her folks at the Foley law firm. [read post]
7 Jan 2010, 1:17 pm
Edward Polk, Courtenay C. [read post]
2 Oct 2009, 8:21 am
" See Jon Dudas to Foley & Lardner DC office See also the IPBiz posts: Kappos and IBM in May 2009 discussing a panel including Foley & Lardner attorneys Jonathan Spivey, Jon Dudas, Courtenay Brinckerhoff, and Sharon Barner, along with IBM's David Kappos (now USPTO director)IP-Watch on Obama IP insiders [read post]
22 Jun 2009, 12:49 am
" The participants included Foley & Lardner attorneys Jonathan Spivey, Jon Dudas, Courtenay Brinckerhoff, and Sharon Barner, along with IBM's David Kappos, now indicated to be the nominee of Barack Obama for undersecretary at Commerce and Director of the USPTO. [read post]
10 Oct 2007, 9:11 pm
Glenn Law and Courtenay C. [read post]
19 Sep 2007, 5:29 am
Brinckerhoff, Partner, Biotechnology & Pharmaceutical Practice; Stephen P. [read post]
29 Aug 2007, 8:52 pm
Elliott and Courtenay C. [read post]
25 Aug 2007, 12:24 pm
Courtenay Brinckerhoff of Foley & Lardner: "The USPTO believes that the new rules [limiting examination] will improve the patent examination process and relieve the overwhelming backlog of pending patent applications, but may have underestimated the substantive impact the rules will have on patent Applicants. [read post]
22 Aug 2007, 10:17 am
I spoke with Courtenay Brinckerhoff at Foley & Lardner briefly about the new rules and she expressed the concern that the rule changes may be especially problematic for the chemical, pharmaceutical and biotech arts. [read post]
